Traws Pharma, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $12.5M
- Price
- $0.53
- % Change (Daily % change from the live per-ticker quote feed.)
- +3.96%
- Volume
- 219.7K
About
Traws Pharma, Inc., a clinical stage biopharmaceutical company, focuses on developing small molecule oral product candidates for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID19 that are designed to address treatment resistance, such as TRX01 (travatrelvir), a Mpro/3CL inhibitor in development for the treatment of COVID19; and TRX100 (viroxavir), an endonuclease inhibitor in development for the treatment of pandemic influenza. It is also developing narazaciclib, a multi-kinase CDK4/6 inhibitor, which is in Phase 1/2 clinical trials in patients with cancer, with or without co-administration of letrozole to define the recommended phase 2 dose for further development in endometrial cancer; and oral rigosertib, which is administered alone or in combination for investigation in various cancers. The company was formerly known as Onconova Therapeutics, Inc. and changed its name to Traws Pharma, Inc. in April 2024. Traws Pharma, Inc. was incorporated in 1998 and is headquartered in Newtown, Pennsylvania.
Quick stats
Shares outstanding15.2M
Computed float11.1M
Float / shares73.6%
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001130598
Websitehttps://www.trawspharma.com
AI Summary
AI-generated1/12
standardmixedearnings
Traws Pharma Reports Q2 2026 Financial Results and Provides Business Highlights
Traws Pharma reported Q2 revenue of $0 compared to $2.7 million in the prior year, while net loss widened to $3.0 million or $0.16 per share due to higher G&A expenses.
Cash and cash equivalents increased to $5.0 million following an April private placement, providing a runway into Q1 2027 before additional financing may be required.
Shareholders approved Series B and C warrant tranches, granting the company access to up to $50 million in additional capital contingent on achieving clinical and regulatory milestones.
Management expects to resubmit a revised toxicology package to the MHRA by the end of Q3 2026 and is preparing a response to the FDA to resolve the clinical hold on its US IND by year-end.
Red flags
- Cash runway extends only into Q1 2027
- FDA clinical hold on tivoxavir marboxil remains unresolved
- Revenue dropped to $0 from $2.7M in the prior-year quarter